George Eric Davis Sells 1,850 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) EVP George Eric Davis sold 1,850 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $85.01, for a total value of $157,268.50. Following the completion of the transaction, the executive vice president now directly owns 56,157 shares in the company, valued at $4,773,906.57. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

George Eric Davis also recently made the following trade(s):

• On Thursday, March 28th, George Eric Davis sold 24,602 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $88.34, for a total value of $2,173,340.68.

BioMarin Pharmaceutical Trading Down 0.4 %

Shares of BioMarin Pharmaceutical stock traded down $0.34 on Monday, reaching $82.10. 882,547 shares of the company were exchanged, compared to its average volume of 1,458,392. The stock has a fifty day moving average price of $86.73 and a 200-day moving average price of $89.02. The firm has a market capitalization of $15.59 billion, a price-to-earnings ratio of 76.73, a price-to-earnings-growth ratio of 1.30 and a beta of 0.34. The company has a current ratio of 2.74, a quick ratio of 1.70 and a debt-to-equity ratio of 0.12. BioMarin Pharmaceutical Inc. has a fifty-two week low of $76.02 and a fifty-two week high of $99.56.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $646.21 million for the quarter, compared to analyst estimates of $639.53 million. BioMarin Pharmaceutical had a return on equity of 5.34% and a net margin of 8.31%. BioMarin Pharmaceutical's quarterly revenue was up 20.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.11 earnings per share. On average, analysts expect that BioMarin Pharmaceutical Inc. will post 1.98 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Piper Sandler reduced their price objective on BioMarin Pharmaceutical from $115.00 to $107.00 and set an "overweight" rating for the company in a research report on Friday, February 23rd. Scotiabank boosted their price objective on shares of BioMarin Pharmaceutical from $83.00 to $85.00 and gave the company a "sector perform" rating in a research report on Thursday, April 25th. Cantor Fitzgerald restated an "overweight" rating and issued a $110.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, April 25th. Morgan Stanley cut their price target on shares of BioMarin Pharmaceutical from $115.00 to $112.00 and set an "overweight" rating on the stock in a report on Friday, April 26th. Finally, Wells Fargo & Company increased their price target on shares of BioMarin Pharmaceutical from $100.00 to $110.00 and gave the company an "overweight" rating in a research report on Thursday, April 25th. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of "Moderate Buy" and an average target price of $107.50.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. KB Financial Partners LLC boosted its stake in BioMarin Pharmaceutical by 51.3% during the 3rd quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 118 shares during the period. Lindbrook Capital LLC boosted its stake in BioMarin Pharmaceutical by 259.8% during the 4th quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 278 shares during the period. Castleview Partners LLC bought a new stake in BioMarin Pharmaceutical during the 3rd quarter valued at approximately $35,000. Benjamin F. Edwards & Company Inc. raised its holdings in BioMarin Pharmaceutical by 135.3% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the biotechnology company's stock valued at $42,000 after acquiring an additional 249 shares in the last quarter. Finally, Jones Financial Companies Lllp acquired a new position in BioMarin Pharmaceutical in the 4th quarter valued at approximately $43,000. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.